Greenwood Capital Associates LLC Invests $531,000 in Novo Nordisk A/S $NVO

Greenwood Capital Associates LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 14,451 shares of the company’s stock, valued at approximately $531,000.

A number of other large investors also recently bought and sold shares of the business. Godfrey Financial Associates Inc. bought a new position in Novo Nordisk A/S in the 4th quarter valued at $25,000. WealthCollab LLC lifted its position in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares during the last quarter. American National Bank & Trust bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth $28,000. Jackson Grant Investment Advisers Inc. purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at $29,000. Finally, Maseco LLP bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Sanford C. Bernstein initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price objective for the company. Weiss Ratings downgraded shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Wolfe Research began coverage on shares of Novo Nordisk A/S in a research report on Thursday, March 26th. They set a “peer perform” rating on the stock. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Finally, Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Five investment analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $48.93 on Friday. The company has a market cap of $218.48 billion, a PE ratio of 11.49, a P/E/G ratio of 4.46 and a beta of 0.77. The firm’s 50 day moving average price is $45.39 and its 200-day moving average price is $45.85. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $71.79.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.38 EPS for the current fiscal year.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk launched Awiqli, the world’s first once-weekly basal insulin, in India, expanding its diabetes portfolio in one of the world’s largest and fastest-growing diabetes markets. The rollout could provide a new growth avenue and reinforces the company’s leadership in diabetes care. Article Title
• Positive Sentiment: Another report highlighted the India insulin launch as a meaningful innovation for diabetes treatment, which may improve investor sentiment around Novo Nordisk’s long-term pipeline and international expansion. Article Title
• Positive Sentiment: A separate piece said Novo Nordisk remains undervalued despite the Wegovy label update, suggesting the market may still be pricing in a cautious outlook even as the company preserves a strong long-term obesity-drug story. Article Title
• Neutral Sentiment: Novo Nordisk also expanded its collaboration with MAHE’s GBS in pharmacometrics, a strategic but likely modest near-term market-moving development. Article Title
• Neutral Sentiment: The company signed a pact with Vivani for a long-lasting semaglutide implant, which adds to its pipeline optionality but is still early-stage and not an immediate earnings driver. Article Title
• Negative Sentiment: Recent prescription-tracker data pointed to a slowdown in demand for the oral Wegovy pill in the U.S., raising concerns that growth in Novo Nordisk’s GLP-1 franchise may be cooling after a strong run. Article Title
• Negative Sentiment: The stock also came under pressure in recent trading after falling more than the broader market, reflecting investor caution around near-term GLP-1 growth trends and valuation. Article Title

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.